A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen, Bet v 1

Trial Profile

A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen, Bet v 1

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2013

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jan 2013 Planned end date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov.
    • 02 Nov 2012 Planned end date changed from 1 Oct 2009 to 1 Jun 2016 as reported by ClinicalTrials.gov.
    • 27 Jul 2007 The expected completion date for this trial is now 1 Oct 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top